Blood Collection Devices MarketSize and Trends

Blood collection devices plays a crucial role in the patient treatment. For the treatment, blood samples are collected to measure the basic metabolism components such as blood urea nitrogen, sodium, potassium, creatinine, magnesium, chloride, and also used to measure blood glucose and lipid levels. In the recent years, as technology has increased in availability and complexity, the experts in the laboratories are receiving wide range of opportunities and challenges. In case of opportunity, automated method of collection enables technologists to perform a greater variety of tests on smaller sample quantities with greater accuracy of outcomes than the manual blood collection process. Therefore, there is an increasing number of laboratories taking their pace in the market from their hematology and chemistry analyzers to automated platforms.

Continuous product advancement in blood collection devices fuel the growth of the market

Tasso, Inc., a company engaged in the manufacture of HemoLink, a simplified blood collection device used in the various diagnostic application received the US$ 3 million funding from Defenses Advanced Research Projects Agency (DARPA) to advances their HemoLink technology by collaborating with GenTegra LLC, a company engaged in the manufacture of product used in the biopreservation, biobanking and in vitro diagnostics. Moreover the continuous product development and future advances in the blood collection techniques are expected to propel the growth of blood collection devices market.

Recent FDA approvals to enter novel and technologically advanced blood collection devices in the market

DBS System SA- granted the USPTO patent for HemaXis Microfluidic blood collection platform in November 2017. HemaXis DB is microfluidic blood collection system, which uses the microfluidic chip with a standard filter card and protective case to provide the practical solution for blood collection procedure.

Seventh Sense Biosystems, Inc. in February 2017 received U.S. FDA clearance for its new blood collection device named Touch Activated Phlebotomy (TAP). TAP is novel blood collection device used for convenient and painless blood testing. Moreover in October 2017, Ionis Pharmaceuticals- a company engaged in the RNA-targeted drug discovery and development to develop drug for severe and orphan disease has made collaboration with Seventh Sense Biosystems to support the development of improved blood collection and diagnostic device. The collaboration enables the further product development of TAP device for blood testing.

Velano Vascular, Inc. - a medical device company manufactures the needle-free, vascular device for blood collection, received the FDA approval for its updated version of needle-free blood draw device. The Velano device is designed to reduce blood draw related anxiety and discomfort in hospital patients allowing safer work environment for healthcare professionals. The FDA approved blood collection devices with their increased acceptability helps to favor the further growth of the market.